---
title: "GRI Bio, Inc. (GRI.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/GRI.US.md"
symbol: "GRI.US"
name: "GRI Bio, Inc."
industry: "Biotechnology"
datetime: "2026-05-19T23:59:56.084Z"
locales:
  - [en](https://longbridge.com/en/quote/GRI.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/GRI.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/GRI.US.md)
---

# GRI Bio, Inc. (GRI.US)

## Company Overview

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.gribio.com](https://www.gribio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.28 | 107 | - | - | - |
| PB | 0.29 | 16 | 2.61 | 1.33 | 0.58 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 41.72 |
| Highest Target | 1120.00 |
| Lowest Target | 280.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/GRI.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/GRI.US/norm.md)
- [Related News](https://longbridge.com/en/quote/GRI.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/GRI.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**